Leishmaniasis (Cutaneous - Leishmania spp.)

Overview

Plain-Language Overview

Cutaneous leishmaniasis is a skin infection caused by parasites called Leishmania species, which are transmitted through the bite of infected sandflies. This condition primarily affects the skin, leading to sores that can start as small bumps and develop into ulcers. These skin lesions often appear on exposed parts of the body such as the face, arms, and legs. The sores may be painless or painful and can leave scars after healing. The infection can affect a person's appearance and sometimes cause discomfort or secondary infections. It is most common in tropical and subtropical regions where sandflies are found.

Clinical Definition

Cutaneous leishmaniasis is a parasitic disease caused by infection with protozoa of the genus Leishmania, transmitted by the bite of infected female sandflies. The core pathology involves the invasion and replication of amastigote forms within macrophages of the skin, leading to localized cutaneous ulcers and chronic skin inflammation. The disease is characterized by one or more painless, well-demarcated skin lesions that may ulcerate and persist for months to years. It is a major cause of morbidity in endemic areas due to disfiguring scars and secondary bacterial infections. Diagnosis relies on identifying the parasite in tissue samples. The condition is significant for its potential to cause chronic skin damage and its epidemiological importance in tropical medicine.

Inciting Event

Bite of an infected female sandfly introduces Leishmania promastigotes into the skin.
Inoculation of parasites during sandfly blood meal initiates local infection.

Latency Period

Incubation period ranges from weeks to months, typically 2 to 8 weeks before lesion development.
Lesions may appear gradually after initial asymptomatic period following sandfly bite.

Diagnostic Delay

Lesions mimic other dermatologic conditions such as bacterial ulcers or fungal infections, leading to misdiagnosis.
Lack of awareness in non-endemic areas delays consideration of leishmaniasis.
Slow progression and painless nature of lesions reduce urgency for medical evaluation.

Clinical Presentation

Signs & Symptoms

Chronic, painless skin ulcers with raised borders and central necrosis are hallmark symptoms.
Initial papules or nodules develop at the sandfly bite site after an incubation period of weeks to months.
Regional lymphadenopathy may accompany skin lesions.
Lesions typically do not cause systemic symptoms unless disseminated or mucocutaneous forms develop.
Lesions may be pruritic or mildly tender but are often asymptomatic.

History of Present Illness

Painless papule at sandfly bite site that enlarges over weeks to form a chronic ulcer with raised, indurated borders.
Lesions are typically solitary but can be multiple and persist for months without spontaneous healing.
No systemic symptoms in cutaneous form, but local lymphadenopathy may be present.

Past Medical History

Previous travel or residence in endemic areas increases suspicion for leishmaniasis.
History of immunosuppressive conditions such as HIV or immunosuppressive therapy may worsen disease course.
Prior skin trauma or insect bites may be relevant but are nonspecific.

Family History

[]

Physical Exam Findings

One or more ulcerative skin lesions with raised, indurated borders and a central crater are typical in cutaneous leishmaniasis.
Painless papules or nodules often develop at the site of the sandfly bite after an incubation period of weeks to months.
Regional lymphadenopathy may be present near the affected skin lesions.
Lesions commonly appear on exposed areas such as the face, arms, and legs.
Chronic lesions may show scarring and pigmentary changes after healing.

Diagnostic Workup

Diagnostic Criteria

Diagnosis is established by demonstrating Leishmania amastigotes in skin lesion samples using microscopic examination of Giemsa-stained smears or histopathology. Culture of the parasite from lesion aspirates or biopsies can confirm the diagnosis. Molecular methods such as PCR provide sensitive and specific detection of Leishmania DNA. Clinical presentation of characteristic chronic skin ulcers in an endemic area supports the diagnosis. Serologic tests are generally less useful for cutaneous forms.

Pathophysiology

Key Mechanisms

Intracellular infection of macrophages by Leishmania promastigotes leads to parasite replication and host cell lysis.
Cell-mediated immunity involving Th1 response and IFN-γ production is critical for controlling infection and lesion resolution.
Delayed-type hypersensitivity reaction causes localized tissue inflammation and ulceration at the site of sandfly bite.
Sandfly vector saliva contains immunomodulatory factors that facilitate parasite entry and immune evasion.

Involvement	Details
Organs	Lymph nodes drain infected skin areas and participate in immune activation against Leishmania
Organs	Spleen can be involved in disseminated disease but is typically spared in cutaneous forms
Tissues	Skin is the primary tissue affected in cutaneous leishmaniasis, where ulcerative lesions develop
Tissues	Subcutaneous tissue may be involved in deeper lesions causing nodules and plaques
Cells	Macrophages serve as the primary host cells where Leishmania parasites replicate intracellularly
	Dendritic cells present Leishmania antigens to T cells initiating adaptive immune responses
	CD4+ T helper 1 cells produce IFN-gamma to activate macrophages for parasite killing
	CD8+ T cells contribute to cytotoxic responses against infected cells
Chemical Mediators	Interferon-gamma (IFN-γ) activates macrophages to enhance intracellular killing of Leishmania
	Tumor necrosis factor-alpha (TNF-α) promotes inflammation and granuloma formation around infected cells
	Interleukin-10 (IL-10) downregulates macrophage activation and can facilitate parasite persistence
	Nitric oxide (NO) produced by activated macrophages is a key microbicidal molecule against Leishmania

Treatments

Pharmacological Treatments

Pentavalent antimonials (e.g., sodium stibogluconate)
- Mechanism:
  - Inhibits parasite glycolysis and fatty acid oxidation leading to parasite death
- Side effects:
  - Cardiotoxicity
  - Pancreatitis
  - Hepatotoxicity
  - Myalgias
- Clinical role:
  - First-line
Liposomal amphotericin B
- Mechanism:
  - Binds ergosterol in parasite membranes causing increased permeability and cell death
- Side effects:
  - Nephrotoxicity
  - Infusion reactions
  - Electrolyte imbalances
- Clinical role:
  - Second-line
Miltefosine
- Mechanism:
  - Disrupts parasite membrane lipid metabolism and induces apoptosis
- Side effects:
  - Gastrointestinal upset
  - Teratogenicity
  - Elevated liver enzymes
- Clinical role:
  - Second-line
Paromomycin
- Mechanism:
  - Inhibits parasite protein synthesis by binding 30S ribosomal subunit
- Side effects:
  - Nephrotoxicity
  - Ototoxicity
  - Local injection site pain
- Clinical role:
  - Adjunctive

Non-pharmacological Treatments

Local wound care including cleaning and dressing of cutaneous ulcers to prevent secondary infection
Thermotherapy using localized heat application to kill parasites in cutaneous lesions
Surgical excision or cryotherapy for small, well-defined cutaneous lesions

Prevention

Pharmacological Prevention

No widely available vaccine exists for cutaneous leishmaniasis prevention.
Prophylactic use of pentavalent antimonials is not recommended due to toxicity and resistance.
Experimental vaccines targeting Leishmania antigens are under investigation but not yet approved.

Non-pharmacological Prevention

Avoidance of sandfly exposure by using insecticide-treated bed nets and protective clothing is key.
Application of insect repellents containing DEET reduces sandfly bites.
Environmental control measures such as insecticide spraying and habitat reduction decrease vector populations.
Screening and early treatment of infected individuals help reduce transmission.
Education about peak sandfly activity times (dusk to dawn) aids in exposure reduction.

Outcome & Complications

Complications

Secondary bacterial infection of ulcerated lesions is common and can worsen tissue damage.
Progression to mucocutaneous leishmaniasis can cause destructive lesions of the nasal and oral mucosa.
Disfiguring scars and pigmentary changes are frequent long-term complications.
Rarely, disseminated cutaneous leishmaniasis occurs in immunocompromised patients.
Chronic lesions may lead to persistent inflammation and fibrosis.

Short-term Sequelae	Long-term Sequelae
Ulceration and local tissue necrosis at the bite site develop within weeks to months. Regional lymphadenopathy may cause localized swelling and discomfort. Acute inflammation can cause erythema and induration around lesions. Secondary bacterial superinfection may cause increased pain and purulence.	Permanent scarring and skin disfigurement are common after lesion healing. Hypopigmentation or hyperpigmentation often persists at lesion sites. Mucosal involvement can cause chronic destructive lesions of the nose and mouth. Psychosocial impact due to visible skin lesions and scars may occur. Rarely, chronic lesions may undergo malignant transformation.

Differential Diagnoses

Leishmaniasis (Cutaneous - Leishmania spp.) versus Cutaneous Tuberculosis

Leishmaniasis (Cutaneous - Leishmania spp.)	Cutaneous Tuberculosis
Exposure to sandflies in endemic tropical or subtropical regions for Leishmania spp.	History of exposure to active pulmonary tuberculosis or endemic area for Mycobacterium tuberculosis
Granulomatous inflammation with intracellular amastigotes (Leishman-Donovan bodies) within macrophages	Granulomatous inflammation with caseating necrosis and acid-fast bacilli on Ziehl-Neelsen stain
Positive microscopic identification of amastigotes on skin lesion smear or PCR for Leishmania DNA	Positive culture or PCR for Mycobacterium tuberculosis

Leishmaniasis (Cutaneous - Leishmania spp.) versus Sporotrichosis

Leishmaniasis (Cutaneous - Leishmania spp.)	Sporotrichosis
History of sandfly bite in endemic areas	History of trauma with plant material or soil exposure, especially rose thorns
Localized ulcerative skin lesion without typical lymphatic spread	Nodular lesions that spread along lymphatic channels (lymphocutaneous pattern)
Microscopic visualization of Leishmania amastigotes or positive PCR	Culture grows Sporothrix schenckii

Leishmaniasis (Cutaneous - Leishmania spp.) versus Cutaneous Anthrax

Leishmaniasis (Cutaneous - Leishmania spp.)	Cutaneous Anthrax
Exposure to sandfly bites in endemic regions	Contact with infected animals or animal products (wool, hides)
Intracellular amastigotes seen on skin lesion smear	Gram-positive bacilli with boxcar-shaped rods on smear and culture positive for Bacillus anthracis
Chronic ulcer with raised indurated borders and slow progression	Rapidly enlarging painless ulcer with characteristic black eschar and significant surrounding edema

Leishmaniasis (Cutaneous - Leishmania spp.) versus Cutaneous Leprosy

Leishmaniasis (Cutaneous - Leishmania spp.)	Cutaneous Leprosy
Exposure to sandflies in endemic tropical or subtropical regions	Residence or travel to areas endemic for Mycobacterium leprae with prolonged close contact
Granulomatous inflammation with intracellular amastigotes without nerve involvement	Granulomatous inflammation with acid-fast bacilli in skin biopsy and nerve involvement
Ulcerative skin lesion without sensory loss or nerve thickening	Hypopigmented or erythematous anesthetic skin patches with peripheral nerve thickening

Leishmaniasis (Cutaneous - Leishmania spp.) versus Pyoderma Gangrenosum

Leishmaniasis (Cutaneous - Leishmania spp.)	Pyoderma Gangrenosum
Slowly progressive painless ulcer with raised indurated edges	Rapidly progressive painful ulcer with undermined violaceous borders often associated with systemic inflammatory diseases
Presence of intracellular Leishmania amastigotes within macrophages	Neutrophilic dermatosis with sterile abscess formation and no infectious organisms
Requires antiparasitic treatment such as amphotericin B or miltefosine	Improvement with immunosuppressive therapy (corticosteroids, cyclosporine)